nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—PLA2G4A—amyotrophic lateral sclerosis	0.677	1	CbGaD
Epirubicin—Congestive cardiomyopathy—Riluzole—amyotrophic lateral sclerosis	0.00846	0.041	CcSEcCtD
Epirubicin—Skin candida—Riluzole—amyotrophic lateral sclerosis	0.0077	0.0373	CcSEcCtD
Epirubicin—CHD1—hindbrain—amyotrophic lateral sclerosis	0.0055	0.136	CbGeAlD
Epirubicin—Proctitis—Riluzole—amyotrophic lateral sclerosis	0.00363	0.0176	CcSEcCtD
Epirubicin—Skin nodule—Riluzole—amyotrophic lateral sclerosis	0.0032	0.0155	CcSEcCtD
Epirubicin—CHD1—brainstem—amyotrophic lateral sclerosis	0.00315	0.0779	CbGeAlD
Epirubicin—Faecalith—Riluzole—amyotrophic lateral sclerosis	0.00311	0.015	CcSEcCtD
Epirubicin—Faecaloma—Riluzole—amyotrophic lateral sclerosis	0.00311	0.015	CcSEcCtD
Epirubicin—Skin mass—Riluzole—amyotrophic lateral sclerosis	0.00286	0.0139	CcSEcCtD
Epirubicin—Hemiplegia—Riluzole—amyotrophic lateral sclerosis	0.00248	0.012	CcSEcCtD
Epirubicin—Rectal tenesmus—Riluzole—amyotrophic lateral sclerosis	0.00238	0.0115	CcSEcCtD
Epirubicin—Hypochromic anaemia—Riluzole—amyotrophic lateral sclerosis	0.00229	0.0111	CcSEcCtD
Epirubicin—CHD1—medulla oblongata—amyotrophic lateral sclerosis	0.0022	0.0543	CbGeAlD
Epirubicin—Fungal skin infection—Riluzole—amyotrophic lateral sclerosis	0.00212	0.0103	CcSEcCtD
Epirubicin—Furunculosis—Riluzole—amyotrophic lateral sclerosis	0.00209	0.0101	CcSEcCtD
Epirubicin—Pericarditis—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00994	CcSEcCtD
Epirubicin—CHD1—spinal cord—amyotrophic lateral sclerosis	0.00196	0.0485	CbGeAlD
Epirubicin—Proctalgia—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00917	CcSEcCtD
Epirubicin—Furuncle—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00877	CcSEcCtD
Epirubicin—Peripheral vascular disorder—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00877	CcSEcCtD
Epirubicin—Muscle relaxant therapy—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00864	CcSEcCtD
Epirubicin—Pneumothorax—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00864	CcSEcCtD
Epirubicin—Bundle branch block—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00852	CcSEcCtD
Epirubicin—Vaginal moniliasis—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00852	CcSEcCtD
Epirubicin—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00173	0.0084	CcSEcCtD
Epirubicin—Vulvovaginal candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00818	CcSEcCtD
Epirubicin—Hypotonia—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00818	CcSEcCtD
Epirubicin—CHD1—nervous system—amyotrophic lateral sclerosis	0.00165	0.0408	CbGeAlD
Epirubicin—Anorectal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00786	CcSEcCtD
Epirubicin—Vulvovaginal mycotic infection—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00786	CcSEcCtD
Epirubicin—Urine abnormality—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00776	CcSEcCtD
Epirubicin—CHD1—central nervous system—amyotrophic lateral sclerosis	0.00159	0.0393	CbGeAlD
Epirubicin—Hypothermia—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00767	CcSEcCtD
Epirubicin—Body temperature decreased—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00767	CcSEcCtD
Epirubicin—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00758	CcSEcCtD
Epirubicin—CHD1—cerebellum—amyotrophic lateral sclerosis	0.00155	0.0384	CbGeAlD
Epirubicin—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00153	0.0074	CcSEcCtD
Epirubicin—Urine analysis abnormal—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00731	CcSEcCtD
Epirubicin—Generalised oedema—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00723	CcSEcCtD
Epirubicin—DHCR7—medulla oblongata—amyotrophic lateral sclerosis	0.00148	0.0366	CbGeAlD
Epirubicin—Enlargement abdomen—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00715	CcSEcCtD
Epirubicin—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00707	CcSEcCtD
Epirubicin—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00684	CcSEcCtD
Epirubicin—Myasthenia—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00684	CcSEcCtD
Epirubicin—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00677	CcSEcCtD
Epirubicin—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00138	0.0067	CcSEcCtD
Epirubicin—YWHAG—medulla oblongata—amyotrophic lateral sclerosis	0.00136	0.0336	CbGeAlD
Epirubicin—AURKA—nervous system—amyotrophic lateral sclerosis	0.00133	0.0329	CbGeAlD
Epirubicin—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00643	CcSEcCtD
Epirubicin—DHCR7—spinal cord—amyotrophic lateral sclerosis	0.00132	0.0327	CbGeAlD
Epirubicin—Hypokinesia—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00637	CcSEcCtD
Epirubicin—Seborrhoeic dermatitis—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00631	CcSEcCtD
Epirubicin—Hyperventilation—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00625	CcSEcCtD
Epirubicin—AURKA—central nervous system—amyotrophic lateral sclerosis	0.00128	0.0317	CbGeAlD
Epirubicin—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00619	CcSEcCtD
Epirubicin—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00619	CcSEcCtD
Epirubicin—CHD1—brain—amyotrophic lateral sclerosis	0.00126	0.0312	CbGeAlD
Epirubicin—Ileus—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00607	CcSEcCtD
Epirubicin—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00607	CcSEcCtD
Epirubicin—Lung disorder—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00607	CcSEcCtD
Epirubicin—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00596	CcSEcCtD
Epirubicin—YWHAG—spinal cord—amyotrophic lateral sclerosis	0.00121	0.03	CbGeAlD
Epirubicin—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00581	CcSEcCtD
Epirubicin—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00576	CcSEcCtD
Epirubicin—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00561	CcSEcCtD
Epirubicin—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00557	CcSEcCtD
Epirubicin—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00552	CcSEcCtD
Epirubicin—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00543	CcSEcCtD
Epirubicin—DHCR7—nervous system—amyotrophic lateral sclerosis	0.00111	0.0275	CbGeAlD
Epirubicin—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00531	CcSEcCtD
Epirubicin—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00531	CcSEcCtD
Epirubicin—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00523	CcSEcCtD
Epirubicin—DHCR7—central nervous system—amyotrophic lateral sclerosis	0.00107	0.0265	CbGeAlD
Epirubicin—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00511	CcSEcCtD
Epirubicin—DHCR7—cerebellum—amyotrophic lateral sclerosis	0.00105	0.0259	CbGeAlD
Epirubicin—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00103	0.005	CcSEcCtD
Epirubicin—YWHAG—nervous system—amyotrophic lateral sclerosis	0.00102	0.0253	CbGeAlD
Epirubicin—AURKA—brain—amyotrophic lateral sclerosis	0.00102	0.0252	CbGeAlD
Epirubicin—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00493	CcSEcCtD
Epirubicin—PLA2G4A—medulla oblongata—amyotrophic lateral sclerosis	0.00101	0.0251	CbGeAlD
Epirubicin—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00489	CcSEcCtD
Epirubicin—YWHAG—central nervous system—amyotrophic lateral sclerosis	0.000984	0.0243	CbGeAlD
Epirubicin—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.000983	0.00476	CcSEcCtD
Epirubicin—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.000983	0.00476	CcSEcCtD
Epirubicin—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.000976	0.00473	CcSEcCtD
Epirubicin—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.000976	0.00473	CcSEcCtD
Epirubicin—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.000969	0.0047	CcSEcCtD
Epirubicin—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.000969	0.0047	CcSEcCtD
Epirubicin—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.000963	0.00466	CcSEcCtD
Epirubicin—YWHAG—cerebellum—amyotrophic lateral sclerosis	0.000962	0.0238	CbGeAlD
Epirubicin—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.000957	0.00463	CcSEcCtD
Epirubicin—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.000938	0.00454	CcSEcCtD
Epirubicin—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.000938	0.00454	CcSEcCtD
Epirubicin—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.000938	0.00454	CcSEcCtD
Epirubicin—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.000909	0.0044	CcSEcCtD
Epirubicin—PLA2G4A—spinal cord—amyotrophic lateral sclerosis	0.000905	0.0224	CbGeAlD
Epirubicin—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.000904	0.00438	CcSEcCtD
Epirubicin—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.000898	0.00435	CcSEcCtD
Epirubicin—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.000888	0.0043	CcSEcCtD
Epirubicin—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.000888	0.0043	CcSEcCtD
Epirubicin—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.000888	0.0043	CcSEcCtD
Epirubicin—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.000888	0.0043	CcSEcCtD
Epirubicin—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000888	0.0043	CcSEcCtD
Epirubicin—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.000882	0.00427	CcSEcCtD
Epirubicin—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.000877	0.00425	CcSEcCtD
Epirubicin—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.000877	0.00425	CcSEcCtD
Epirubicin—Melaena—Riluzole—amyotrophic lateral sclerosis	0.000867	0.0042	CcSEcCtD
Epirubicin—DHCR7—brain—amyotrophic lateral sclerosis	0.000851	0.021	CbGeAlD
Epirubicin—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.000847	0.0041	CcSEcCtD
Epirubicin—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.000843	0.00408	CcSEcCtD
Epirubicin—YWHAG—Regulation of PLK1 Activity at G2/M Transition—DCTN1—amyotrophic lateral sclerosis	0.000841	0.011	CbGpPWpGaD
Epirubicin—AURKA—G2/M Transition—DCTN1—amyotrophic lateral sclerosis	0.000833	0.0109	CbGpPWpGaD
Epirubicin—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.000833	0.00404	CcSEcCtD
Epirubicin—TOP2A—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.000823	0.0108	CbGpPWpGaD
Epirubicin—AURKA—Mitotic G2-G2/M phases—DCTN1—amyotrophic lateral sclerosis	0.000822	0.0108	CbGpPWpGaD
Epirubicin—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.000815	0.00395	CcSEcCtD
Epirubicin—Coma—Riluzole—amyotrophic lateral sclerosis	0.000811	0.00393	CcSEcCtD
Epirubicin—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.000802	0.00389	CcSEcCtD
Epirubicin—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.000802	0.00389	CcSEcCtD
Epirubicin—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00079	0.00383	CcSEcCtD
Epirubicin—YWHAG—brain—amyotrophic lateral sclerosis	0.000781	0.0193	CbGeAlD
Epirubicin—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.000778	0.00377	CcSEcCtD
Epirubicin—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.00077	0.00373	CcSEcCtD
Epirubicin—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00077	0.00373	CcSEcCtD
Epirubicin—PLA2G4A—nervous system—amyotrophic lateral sclerosis	0.000762	0.0188	CbGeAlD
Epirubicin—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.000755	0.00366	CcSEcCtD
Epirubicin—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.000748	0.00362	CcSEcCtD
Epirubicin—YWHAG—Membrane Trafficking—VTA1—amyotrophic lateral sclerosis	0.000746	0.00977	CbGpPWpGaD
Epirubicin—YWHAG—G2/M Transition—TUBA4A—amyotrophic lateral sclerosis	0.000743	0.00973	CbGpPWpGaD
Epirubicin—YWHAG—G2/M Transition—OPTN—amyotrophic lateral sclerosis	0.000743	0.00973	CbGpPWpGaD
Epirubicin—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.000741	0.00359	CcSEcCtD
Epirubicin—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.000741	0.00359	CcSEcCtD
Epirubicin—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.000737	0.00357	CcSEcCtD
Epirubicin—PLA2G4A—central nervous system—amyotrophic lateral sclerosis	0.000734	0.0181	CbGeAlD
Epirubicin—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.000734	0.00355	CcSEcCtD
Epirubicin—YWHAG—Mitotic G2-G2/M phases—OPTN—amyotrophic lateral sclerosis	0.000732	0.0096	CbGpPWpGaD
Epirubicin—YWHAG—Mitotic G2-G2/M phases—TUBA4A—amyotrophic lateral sclerosis	0.000732	0.0096	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—RAB5A—amyotrophic lateral sclerosis	0.000732	0.0096	CbGpPWpGaD
Epirubicin—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00072	0.00349	CcSEcCtD
Epirubicin—Eczema—Riluzole—amyotrophic lateral sclerosis	0.000717	0.00347	CcSEcCtD
Epirubicin—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00071	0.00344	CcSEcCtD
Epirubicin—YWHAG—Membrane Trafficking—KIFAP3—amyotrophic lateral sclerosis	0.000707	0.00927	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.000704	0.00922	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000694	0.0091	CbGpPWpGaD
Epirubicin—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.000686	0.00332	CcSEcCtD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—RAB5A—amyotrophic lateral sclerosis	0.000683	0.00895	CbGpPWpGaD
Epirubicin—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.000683	0.00331	CcSEcCtD
Epirubicin—YWHAG—Membrane Trafficking—IGF2R—amyotrophic lateral sclerosis	0.000675	0.00884	CbGpPWpGaD
Epirubicin—Purpura—Riluzole—amyotrophic lateral sclerosis	0.000668	0.00324	CcSEcCtD
Epirubicin—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.000666	0.00322	CcSEcCtD
Epirubicin—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00066	0.0032	CcSEcCtD
Epirubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—IGFBP3—amyotrophic lateral sclerosis	0.000658	0.00862	CbGpPWpGaD
Epirubicin—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.000647	0.00313	CcSEcCtD
Epirubicin—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.000644	0.00312	CcSEcCtD
Epirubicin—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000644	0.00312	CcSEcCtD
Epirubicin—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.000644	0.00312	CcSEcCtD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—RAB5A—amyotrophic lateral sclerosis	0.000637	0.00835	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000635	0.00832	CbGpPWpGaD
Epirubicin—Migraine—Riluzole—amyotrophic lateral sclerosis	0.000634	0.00307	CcSEcCtD
Epirubicin—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.000634	0.00307	CcSEcCtD
Epirubicin—YWHAG—G2/M Transition—DCTN1—amyotrophic lateral sclerosis	0.000632	0.00828	CbGpPWpGaD
Epirubicin—YWHAG—Mitotic G2-G2/M phases—DCTN1—amyotrophic lateral sclerosis	0.000623	0.00816	CbGpPWpGaD
Epirubicin—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.000622	0.00301	CcSEcCtD
Epirubicin—PLA2G4A—Phospholipid metabolism—SACM1L—amyotrophic lateral sclerosis	0.000621	0.00813	CbGpPWpGaD
Epirubicin—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.000613	0.00297	CcSEcCtD
Epirubicin—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00061	0.00296	CcSEcCtD
Epirubicin—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.000606	0.00293	CcSEcCtD
Epirubicin—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.000599	0.0029	CcSEcCtD
Epirubicin—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.000595	0.00288	CcSEcCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00059	0.00774	CbGpPWpGaD
Epirubicin—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.000588	0.00285	CcSEcCtD
Epirubicin—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.000586	0.00284	CcSEcCtD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—ATF1—amyotrophic lateral sclerosis	0.000585	0.00767	CbGpPWpGaD
Epirubicin—PLA2G4A—Phospholipid metabolism—FIG4—amyotrophic lateral sclerosis	0.000584	0.00765	CbGpPWpGaD
Epirubicin—PLA2G4A—brain—amyotrophic lateral sclerosis	0.000583	0.0144	CbGeAlD
Epirubicin—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.000582	0.00282	CcSEcCtD
Epirubicin—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00058	0.00281	CcSEcCtD
Epirubicin—PLA2G4A—Glycerophospholipid biosynthesis—PLB1—amyotrophic lateral sclerosis	0.000573	0.00751	CbGpPWpGaD
Epirubicin—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00057	0.00276	CcSEcCtD
Epirubicin—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.000568	0.00275	CcSEcCtD
Epirubicin—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.000568	0.00275	CcSEcCtD
Epirubicin—YWHAG—Membrane Trafficking—CHMP2B—amyotrophic lateral sclerosis	0.000565	0.00741	CbGpPWpGaD
Epirubicin—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.000561	0.00272	CcSEcCtD
Epirubicin—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.000557	0.0027	CcSEcCtD
Epirubicin—Asthma—Riluzole—amyotrophic lateral sclerosis	0.000557	0.0027	CcSEcCtD
Epirubicin—Influenza—Riluzole—amyotrophic lateral sclerosis	0.000557	0.0027	CcSEcCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000555	0.00727	CbGpPWpGaD
Epirubicin—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.000546	0.00264	CcSEcCtD
Epirubicin—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.000542	0.00263	CcSEcCtD
Epirubicin—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.000535	0.00259	CcSEcCtD
Epirubicin—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.000529	0.00256	CcSEcCtD
Epirubicin—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.000521	0.00252	CcSEcCtD
Epirubicin—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.000521	0.00252	CcSEcCtD
Epirubicin—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.000514	0.00249	CcSEcCtD
Epirubicin—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.000508	0.00246	CcSEcCtD
Epirubicin—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.000507	0.00245	CcSEcCtD
Epirubicin—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.000504	0.00244	CcSEcCtD
Epirubicin—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.000499	0.00242	CcSEcCtD
Epirubicin—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.000496	0.0024	CcSEcCtD
Epirubicin—Infestation—Riluzole—amyotrophic lateral sclerosis	0.000496	0.0024	CcSEcCtD
Epirubicin—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.000487	0.00236	CcSEcCtD
Epirubicin—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.000484	0.00234	CcSEcCtD
Epirubicin—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.000484	0.00234	CcSEcCtD
Epirubicin—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.000483	0.00234	CcSEcCtD
Epirubicin—Sweating—Riluzole—amyotrophic lateral sclerosis	0.000476	0.00231	CcSEcCtD
Epirubicin—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.000473	0.00229	CcSEcCtD
Epirubicin—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00047	0.00227	CcSEcCtD
Epirubicin—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000468	0.00227	CcSEcCtD
Epirubicin—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.000466	0.00226	CcSEcCtD
Epirubicin—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.000463	0.00224	CcSEcCtD
Epirubicin—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.000454	0.0022	CcSEcCtD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000454	0.00594	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000454	0.00594	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000454	0.00594	CbGpPWpGaD
Epirubicin—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.000448	0.00217	CcSEcCtD
Epirubicin—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.000447	0.00216	CcSEcCtD
Epirubicin—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000446	0.00216	CcSEcCtD
Epirubicin—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000446	0.00216	CcSEcCtD
Epirubicin—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.000443	0.00215	CcSEcCtD
Epirubicin—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.000442	0.00214	CcSEcCtD
Epirubicin—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00044	0.00213	CcSEcCtD
Epirubicin—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.000439	0.00213	CcSEcCtD
Epirubicin—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.000438	0.00212	CcSEcCtD
Epirubicin—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000437	0.00212	CcSEcCtD
Epirubicin—PLA2G4A—Glycerophospholipid biosynthesis—CHAT—amyotrophic lateral sclerosis	0.000435	0.00569	CbGpPWpGaD
Epirubicin—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000421	0.00204	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000419	0.00549	CbGpPWpGaD
Epirubicin—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000416	0.00202	CcSEcCtD
Epirubicin—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000414	0.002	CcSEcCtD
Epirubicin—ABCC1—cerebellum—amyotrophic lateral sclerosis	0.00041	0.0101	CbGeAlD
Epirubicin—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000404	0.00196	CcSEcCtD
Epirubicin—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000403	0.00195	CcSEcCtD
Epirubicin—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000402	0.00195	CcSEcCtD
Epirubicin—YWHAG—ErbB1 downstream signaling—ATF1—amyotrophic lateral sclerosis	0.000401	0.00526	CbGpPWpGaD
Epirubicin—PLA2G4A—Phospholipid metabolism—PLB1—amyotrophic lateral sclerosis	0.0004	0.00524	CbGpPWpGaD
Epirubicin—Chills—Riluzole—amyotrophic lateral sclerosis	0.0004	0.00194	CcSEcCtD
Epirubicin—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000398	0.00193	CcSEcCtD
Epirubicin—YWHAG—Apoptosis—MAPT—amyotrophic lateral sclerosis	0.000397	0.0052	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—ATF1—amyotrophic lateral sclerosis	0.000396	0.00519	CbGpPWpGaD
Epirubicin—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000394	0.00191	CcSEcCtD
Epirubicin—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00039	0.00189	CcSEcCtD
Epirubicin—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000388	0.00188	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—RAB5A—amyotrophic lateral sclerosis	0.000386	0.00506	CbGpPWpGaD
Epirubicin—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000382	0.00185	CcSEcCtD
Epirubicin—Tension—Riluzole—amyotrophic lateral sclerosis	0.000381	0.00184	CcSEcCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.00038	0.00499	CbGpPWpGaD
Epirubicin—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00038	0.00184	CcSEcCtD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000377	0.00494	CbGpPWpGaD
Epirubicin—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.000377	0.00183	CcSEcCtD
Epirubicin—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000375	0.00182	CcSEcCtD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—ATF1—amyotrophic lateral sclerosis	0.000374	0.0049	CbGpPWpGaD
Epirubicin—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000373	0.00181	CcSEcCtD
Epirubicin—YWHAG—Intrinsic Pathway for Apoptosis—CASP3—amyotrophic lateral sclerosis	0.000363	0.00475	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000363	0.00475	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—IGFBP3—amyotrophic lateral sclerosis	0.000362	0.00475	CbGpPWpGaD
Epirubicin—AURKA—Aurora A signaling—TP53—amyotrophic lateral sclerosis	0.000361	0.00473	CbGpPWpGaD
Epirubicin—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00036	0.00174	CcSEcCtD
Epirubicin—UGT2B7—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00036	0.00472	CbGpPWpGaD
Epirubicin—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000359	0.00174	CcSEcCtD
Epirubicin—Agitation—Riluzole—amyotrophic lateral sclerosis	0.000357	0.00173	CcSEcCtD
Epirubicin—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00035	0.00169	CcSEcCtD
Epirubicin—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000349	0.00169	CcSEcCtD
Epirubicin—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000348	0.00169	CcSEcCtD
Epirubicin—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000347	0.00168	CcSEcCtD
Epirubicin—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000343	0.00166	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000341	0.00447	CbGpPWpGaD
Epirubicin—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000341	0.00165	CcSEcCtD
Epirubicin—Cough—Riluzole—amyotrophic lateral sclerosis	0.000339	0.00164	CcSEcCtD
Epirubicin—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000336	0.00163	CcSEcCtD
Epirubicin—PLA2G4A—AGE/RAGE pathway—CASP9—amyotrophic lateral sclerosis	0.000336	0.0044	CbGpPWpGaD
Epirubicin—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000335	0.00162	CcSEcCtD
Epirubicin—ABCC1—brain—amyotrophic lateral sclerosis	0.000333	0.00824	CbGeAlD
Epirubicin—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00033	0.0016	CcSEcCtD
Epirubicin—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00033	0.0016	CcSEcCtD
Epirubicin—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00033	0.0016	CcSEcCtD
Epirubicin—ABCC1—S1P1 pathway—PTGS2—amyotrophic lateral sclerosis	0.00033	0.00432	CbGpPWpGaD
Epirubicin—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000329	0.00159	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000328	0.00159	CcSEcCtD
Epirubicin—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000326	0.00158	CcSEcCtD
Epirubicin—YWHAG—Activation of BH3-only proteins—TP53—amyotrophic lateral sclerosis	0.000325	0.00426	CbGpPWpGaD
Epirubicin—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000323	0.00156	CcSEcCtD
Epirubicin—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000319	0.00155	CcSEcCtD
Epirubicin—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000317	0.00153	CcSEcCtD
Epirubicin—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000317	0.00153	CcSEcCtD
Epirubicin—Infection—Riluzole—amyotrophic lateral sclerosis	0.000315	0.00152	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—TUBA4A—amyotrophic lateral sclerosis	0.000312	0.00409	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—OPTN—amyotrophic lateral sclerosis	0.000312	0.00409	CbGpPWpGaD
Epirubicin—Shock—Riluzole—amyotrophic lateral sclerosis	0.000312	0.00151	CcSEcCtD
Epirubicin—UGT2B7—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000311	0.00408	CbGpPWpGaD
Epirubicin—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000311	0.0015	CcSEcCtD
Epirubicin—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00031	0.0015	CcSEcCtD
Epirubicin—DHCR7—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000309	0.00405	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000309	0.00405	CbGpPWpGaD
Epirubicin—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000309	0.0015	CcSEcCtD
Epirubicin—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000308	0.00149	CcSEcCtD
Epirubicin—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000306	0.00148	CcSEcCtD
Epirubicin—PLA2G4A—Phospholipid metabolism—CHAT—amyotrophic lateral sclerosis	0.000303	0.00397	CbGpPWpGaD
Epirubicin—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000302	0.00146	CcSEcCtD
Epirubicin—PLA2G4A—AGE/RAGE pathway—SOD1—amyotrophic lateral sclerosis	0.000301	0.00395	CbGpPWpGaD
Epirubicin—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000296	0.00143	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000296	0.00387	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—ATF1—amyotrophic lateral sclerosis	0.000294	0.00385	CbGpPWpGaD
Epirubicin—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000288	0.0014	CcSEcCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000288	0.00378	CbGpPWpGaD
Epirubicin—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000286	0.00139	CcSEcCtD
Epirubicin—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.000286	0.00375	CbGpPWpGaD
Epirubicin—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000284	0.00138	CcSEcCtD
Epirubicin—DHCR7—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000283	0.00371	CbGpPWpGaD
Epirubicin—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000282	0.00137	CcSEcCtD
Epirubicin—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000281	0.00136	CcSEcCtD
Epirubicin—YWHAG—Apoptosis—CASP9—amyotrophic lateral sclerosis	0.00028	0.00367	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—TUBA4A—amyotrophic lateral sclerosis	0.000279	0.00365	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—OPTN—amyotrophic lateral sclerosis	0.000279	0.00365	CbGpPWpGaD
Epirubicin—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000279	0.00135	CcSEcCtD
Epirubicin—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000275	0.00133	CcSEcCtD
Epirubicin—YWHAG—Role of Calcineurin-dependent NFAT signaling in lymphocytes—CASP3—amyotrophic lateral sclerosis	0.000274	0.00359	CbGpPWpGaD
Epirubicin—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000273	0.00132	CcSEcCtD
Epirubicin—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000273	0.00132	CcSEcCtD
Epirubicin—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000271	0.00131	CcSEcCtD
Epirubicin—Pain—Riluzole—amyotrophic lateral sclerosis	0.000271	0.00131	CcSEcCtD
Epirubicin—ABCC1—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.00027	0.00353	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000267	0.0035	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—DCTN1—amyotrophic lateral sclerosis	0.000265	0.00347	CbGpPWpGaD
Epirubicin—UGT2B7—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000263	0.00345	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—TUBA4A—amyotrophic lateral sclerosis	0.000263	0.00345	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000263	0.00345	CbGpPWpGaD
Epirubicin—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000261	0.00126	CcSEcCtD
Epirubicin—ABCC1—S1P1 pathway—VEGFA—amyotrophic lateral sclerosis	0.00026	0.0034	CbGpPWpGaD
Epirubicin—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000259	0.00125	CcSEcCtD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—amyotrophic lateral sclerosis	0.000253	0.00331	CbGpPWpGaD
Epirubicin—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000252	0.00122	CcSEcCtD
Epirubicin—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00025	0.00121	CcSEcCtD
Epirubicin—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00025	0.00121	CcSEcCtD
Epirubicin—DHCR7—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000247	0.00324	CbGpPWpGaD
Epirubicin—UGT2B7—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.000238	0.00312	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—DCTN1—amyotrophic lateral sclerosis	0.000237	0.00311	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—PFN1—amyotrophic lateral sclerosis	0.000237	0.0031	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—TUBA4A—amyotrophic lateral sclerosis	0.000236	0.0031	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—OPTN—amyotrophic lateral sclerosis	0.000236	0.0031	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000235	0.00308	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000235	0.00308	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000235	0.00308	CbGpPWpGaD
Epirubicin—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000233	0.00113	CcSEcCtD
Epirubicin—YWHAG—Intrinsic Pathway for Apoptosis—TP53—amyotrophic lateral sclerosis	0.000233	0.00305	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000228	0.00298	CbGpPWpGaD
Epirubicin—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000227	0.0011	CcSEcCtD
Epirubicin—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000224	0.00109	CcSEcCtD
Epirubicin—DHCR7—Metabolism—DAO—amyotrophic lateral sclerosis	0.000224	0.00293	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000219	0.00286	CbGpPWpGaD
Epirubicin—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000217	0.00105	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000215	0.00282	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000214	0.00281	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TUBA4A—amyotrophic lateral sclerosis	0.000211	0.00277	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—OPTN—amyotrophic lateral sclerosis	0.000211	0.00277	CbGpPWpGaD
Epirubicin—YWHAG—LKB1 signaling events—TP53—amyotrophic lateral sclerosis	0.000211	0.00276	CbGpPWpGaD
Epirubicin—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000209	0.00101	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000203	0.00266	CbGpPWpGaD
Epirubicin—UGT2B7—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000203	0.00266	CbGpPWpGaD
Epirubicin—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000201	0.000975	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—DCTN1—amyotrophic lateral sclerosis	0.000201	0.00263	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.0002	0.00262	CbGpPWpGaD
Epirubicin—Rash—Riluzole—amyotrophic lateral sclerosis	0.0002	0.000967	CcSEcCtD
Epirubicin—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000199	0.000966	CcSEcCtD
Epirubicin—Headache—Riluzole—amyotrophic lateral sclerosis	0.000198	0.000961	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000197	0.00259	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.000196	0.00256	CbGpPWpGaD
Epirubicin—TOP2A—Gastric Cancer Network 2—TP53—amyotrophic lateral sclerosis	0.000192	0.00251	CbGpPWpGaD
Epirubicin—PLA2G4A—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.00019	0.00249	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—amyotrophic lateral sclerosis	0.000189	0.00248	CbGpPWpGaD
Epirubicin—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000188	0.000911	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000188	0.00246	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000188	0.00246	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000186	0.00243	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—DCTN1—amyotrophic lateral sclerosis	0.00018	0.00235	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000172	0.00225	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000169	0.00222	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000166	0.00217	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—TUBA4A—amyotrophic lateral sclerosis	0.000165	0.00217	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—OPTN—amyotrophic lateral sclerosis	0.000165	0.00217	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00016	0.00209	CbGpPWpGaD
Epirubicin—UGT2B7—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000159	0.00208	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000159	0.00208	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—GSR—amyotrophic lateral sclerosis	0.000156	0.00205	CbGpPWpGaD
Epirubicin—ABCC1—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000152	0.00199	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	0.000151	0.00197	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.00015	0.00197	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TUBA4A—amyotrophic lateral sclerosis	0.000148	0.00194	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—OPTN—amyotrophic lateral sclerosis	0.000148	0.00194	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000143	0.00188	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000142	0.00187	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—CASP3—amyotrophic lateral sclerosis	0.000141	0.00185	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—DCTN1—amyotrophic lateral sclerosis	0.000141	0.00184	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.00014	0.00183	CbGpPWpGaD
Epirubicin—UGT2B7—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000139	0.00183	CbGpPWpGaD
Epirubicin—UGT2B7—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000137	0.0018	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000136	0.00178	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000135	0.00177	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000135	0.00177	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—MMP9—amyotrophic lateral sclerosis	0.000134	0.00175	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000133	0.00175	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000129	0.00169	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000128	0.00168	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000126	0.00165	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—DCTN1—amyotrophic lateral sclerosis	0.000126	0.00165	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000122	0.0016	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000121	0.00158	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—CASP3—amyotrophic lateral sclerosis	0.000118	0.00154	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000117	0.00154	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000117	0.00154	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.000115	0.0015	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000107	0.0014	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000107	0.0014	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—amyotrophic lateral sclerosis	0.000106	0.00138	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000105	0.00137	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000105	0.00137	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000103	0.00135	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000102	0.00133	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TPK1—amyotrophic lateral sclerosis	9.99e-05	0.00131	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	9.95e-05	0.0013	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—VAPA—amyotrophic lateral sclerosis	9.76e-05	0.00128	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	9.76e-05	0.00128	CbGpPWpGaD
Epirubicin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—amyotrophic lateral sclerosis	9.76e-05	0.00128	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—VAPA—amyotrophic lateral sclerosis	9.57e-05	0.00125	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.08e-05	0.00119	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	9.06e-05	0.00119	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—SACM1L—amyotrophic lateral sclerosis	8.9e-05	0.00117	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	8.72e-05	0.00114	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—FIG4—amyotrophic lateral sclerosis	8.53e-05	0.00112	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—amyotrophic lateral sclerosis	8.39e-05	0.0011	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—FIG4—amyotrophic lateral sclerosis	8.37e-05	0.0011	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—VAPB—amyotrophic lateral sclerosis	8.36e-05	0.0011	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—TPK1—amyotrophic lateral sclerosis	8.36e-05	0.0011	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	8.03e-05	0.00105	CbGpPWpGaD
Epirubicin—ABCC1—Disease—VTA1—amyotrophic lateral sclerosis	7.98e-05	0.00105	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	7.85e-05	0.00103	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	7.8e-05	0.00102	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—DAO—amyotrophic lateral sclerosis	7.72e-05	0.00101	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—VAPA—amyotrophic lateral sclerosis	7.65e-05	0.001	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—DAO—amyotrophic lateral sclerosis	7.57e-05	0.000992	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—TP53—amyotrophic lateral sclerosis	7.56e-05	0.00099	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	7.51e-05	0.000984	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	7.42e-05	0.000972	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	7.42e-05	0.000972	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.11e-05	0.000932	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	6.98e-05	0.000915	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	6.97e-05	0.000914	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.9e-05	0.000904	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—FIG4—amyotrophic lateral sclerosis	6.69e-05	0.000876	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	6.61e-05	0.000866	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	6.51e-05	0.000853	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.34e-05	0.000831	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	6.15e-05	0.000806	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CHMP2B—amyotrophic lateral sclerosis	6.05e-05	0.000793	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—DAO—amyotrophic lateral sclerosis	6.05e-05	0.000792	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	6.04e-05	0.000792	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	5.92e-05	0.000775	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—SOD1—amyotrophic lateral sclerosis	5.9e-05	0.000774	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PLB1—amyotrophic lateral sclerosis	5.85e-05	0.000766	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PLB1—amyotrophic lateral sclerosis	5.74e-05	0.000752	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PLB1—amyotrophic lateral sclerosis	5.47e-05	0.000717	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GSR—amyotrophic lateral sclerosis	5.4e-05	0.000707	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—GSR—amyotrophic lateral sclerosis	5.29e-05	0.000694	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—APOE—amyotrophic lateral sclerosis	5.22e-05	0.000684	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	5.13e-05	0.000672	CbGpPWpGaD
Epirubicin—ABCC1—Disease—VCP—amyotrophic lateral sclerosis	4.88e-05	0.000639	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	4.8e-05	0.000628	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PLB1—amyotrophic lateral sclerosis	4.58e-05	0.000601	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	4.56e-05	0.000598	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	4.51e-05	0.000591	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	4.47e-05	0.000586	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CHAT—amyotrophic lateral sclerosis	4.43e-05	0.000581	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CHAT—amyotrophic lateral sclerosis	4.35e-05	0.00057	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	4.29e-05	0.000563	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	4.27e-05	0.00056	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GSR—amyotrophic lateral sclerosis	4.23e-05	0.000554	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	4.14e-05	0.000542	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.97e-05	0.00052	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.87e-05	0.000508	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.85e-05	0.000505	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	3.68e-05	0.000482	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—TP53—amyotrophic lateral sclerosis	3.65e-05	0.000479	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	3.63e-05	0.000476	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—IGF1—amyotrophic lateral sclerosis	3.6e-05	0.000472	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.58e-05	0.000469	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CST3—amyotrophic lateral sclerosis	3.5e-05	0.000459	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CHAT—amyotrophic lateral sclerosis	3.47e-05	0.000455	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.17e-05	0.000415	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—amyotrophic lateral sclerosis	2.77e-05	0.000363	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.72e-05	0.000356	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.69e-05	0.000352	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CASP9—amyotrophic lateral sclerosis	2.55e-05	0.000334	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.5e-05	0.000327	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.38e-05	0.000312	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—VEGFA—amyotrophic lateral sclerosis	2.35e-05	0.000308	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.34e-05	0.000307	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.34e-05	0.000306	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.23e-05	0.000292	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.19e-05	0.000287	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ERBB4—amyotrophic lateral sclerosis	2.18e-05	0.000285	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.17e-05	0.000285	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TP53—amyotrophic lateral sclerosis	1.94e-05	0.000254	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.91e-05	0.00025	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.87e-05	0.000245	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—APOE—amyotrophic lateral sclerosis	1.8e-05	0.000236	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TP53—amyotrophic lateral sclerosis	1.78e-05	0.000233	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—APOE—amyotrophic lateral sclerosis	1.77e-05	0.000231	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.72e-05	0.000225	CbGpPWpGaD
Epirubicin—ABCC1—Disease—APOE—amyotrophic lateral sclerosis	1.69e-05	0.000221	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.59e-05	0.000208	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.48e-05	0.000194	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—APOE—amyotrophic lateral sclerosis	1.41e-05	0.000185	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.23e-05	0.000162	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.22e-05	0.00016	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.21e-05	0.000159	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTGS2—amyotrophic lateral sclerosis	1.15e-05	0.000151	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.67e-06	0.000127	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.39e-06	0.000123	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.88e-06	0.000116	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.97e-06	0.000104	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.02e-06	7.89e-05	CbGpPWpGaD
